Navire Pharma launched with $30mm Series A from parent BridgeBio
Navire Pharma (small-molecule cancer therapies) has launched with a $30mm Series A investment from parent BridgeBio Pharma, plus IP and a drug development team from MD Anderson Cancer Center.
- Venture Financing
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.